• Publications
  • Influence
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
TLDR
Somatostatin antagonist radiotracers are preferable over agonists for the in vivo targeting of sst3- or sst2-expressing tumors, and antagonists for other peptide receptors need to be evaluated in nuclear oncology as a result of this paradigm shift.
Synthesis and Evaluation of Bombesin Derivatives on the Basis of Pan-Bombesin Peptides Labeled with Indium-111, Lutetium-177, and Yttrium-90 for Targeting Bombesin Receptor-Expressing Tumors
TLDR
These radiopeptides were composed of the first pan-bombesin radioligands, which show great promise for the early diagnosis of tumors bearing not only gastrin-releasing peptide-receptor–positive organs but also the other two bombesin receptor subtypes and may be of use in targeted radiotherapy of these tumors.
Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis
TLDR
Improved sensitivity; direct correlation of PET signal with an established biomarker (CD68); ability to readily quantify the PET signal, perform whole-body vascular surveys, and spatially localize and follow the trireporter by microscopy; and clinical translatability of the agent given similarities to magnetic resonance imaging probes in clinical trials are established.
18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis.
TLDR
(18)F-4V allows noninvasive PET-CT imaging of VCAM-1 in inflammatory atherosclerosis, has the dynamic range to quantify treatment effects, and correlates with inflammatory gene expression.
NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.
TLDR
The results indicate an improved biological behavior which is likely due to the fact that an additional spacer group separates the chelate from the pharmacophoric part of the somatostatin analogue.
DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours
TLDR
The newly designed ligands have high potential with regard to PET and SPECT imaging with 68/67Ga and targeted radionuclide therapy with 177Lu and showed good affinity to GRP and neuromedin B receptors but no affinity to BB3.
A Comparison of the Imaging Characteristics and Microregional Distribution of 4 Hypoxia PET Tracers
TLDR
The fluorinated nitroimidazoles showed similar tumor distributions when compared with immunohistochemistry markers of hypoxia, suggesting variations in tumor standardized uptake value and normal tissue distribution may determine the most appropriate clinical setting for each tracer.
Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo
TLDR
It is demonstrated that PET imaging in vivo with the glutamine analog 4-18F-(2S,4R)-fluoroglutamine (18F-FGln) shows high uptake in gliomas but low background brain uptake, facilitating clear tumor delineation.
Indication for Different Mechanisms of Kidney Uptake of Radiolabeled Peptides
TLDR
Inhibition of renal accumulation of the radiopeptides tested could be achieved by either Lys or PGA but not by both at the same time, suggesting 2 different uptake mechanisms.
GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog.
TLDR
The promising in vivo data of 68Ga-BZH3 indicate its potential for an improved localization of GRP-r-positive tumors and also suggest its application in patients.
...
1
2
3
4
5
...